stoxline Quote Chart Rank Option Currency Glossary
  
Talis Biomedical Corporation (TLIS)
9.21  -0.09 (-0.97%)    05-08 16:00
Open: 9.32
High: 9.59
Volume: 4,114
  
Pre. Close: 9.3
Low: 9.05
Market Cap: 17(M)
Technical analysis
2024-05-08 4:56:23 PM
Short term     
Mid term     
Targets 6-month :  11.2 1-year :  13.08
Resists First :  9.59 Second :  11.2
Pivot price 9.05
Supports First :  8.61 Second :  8.01
MAs MA(5) :  9.18 MA(20) :  8.91
MA(100) :  8.36 MA(250) :  7.35
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  73.8 D(3) :  77.7
RSI RSI(14): 58.5
52-week High :  9.59 Low :  4.34
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ TLIS ] has closed below upper band by 25.4%. Bollinger Bands are 47.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.6 - 9.65 9.65 - 9.68
Low: 8.94 - 9 9 - 9.04
Close: 9.12 - 9.21 9.21 - 9.28
Company Description

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.

Headline News

Wed, 08 May 2024
TLIS Stock Earnings: Talis Biomedical Reported Results for Q1 2024 - MSN

Wed, 08 May 2024
Talis: Q1 Earnings Snapshot | National News | clintonherald.com - Clinton Herald

Sat, 04 May 2024
(TLIS) Investment Analysis and Advice - Stock Traders Daily

Sat, 27 Apr 2024
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Talis, TaskUs, and RTR on Behalf of Long-Term ... - GlobeNewswire

Wed, 21 Jun 2023
TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Talis Biomedical Corporation on Behalf of Long-Term ... - Business Wire

Tue, 10 May 2022
Talis Biomedical Announces First Quarter 2022 Financial Results - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 0 (M)
Shares Float 2 (M)
Held by Insiders 1.01e+006 (%)
Held by Institutions 8.3 (%)
Shares Short 14 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -6.328e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -7 %
Return on Assets (ttm) 413.3 %
Return on Equity (ttm) -30.4 %
Qtrly Rev. Growth 2.13e+006 %
Gross Profit (p.s.) -13.86
Sales Per Share -36.4
EBITDA (p.s.) 0
Qtrly Earnings Growth -34.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -53 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.26
Price to Cash Flow 0.42
Stock Dividends
Dividend 0
Forward Dividend 12260
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android